Nano delivery systems and cancer immunotherapy

논문상세정보
    • 저자 Quoc?Viet Le 최진주 오유경
    • 제어번호 105906454
    • 학술지명 Journal of Pharmaceutical Investigation
    • 권호사항 Vol. 48 No. 5 [ 2018 ]
    • 발행처 한국약제학회
    • 발행처 URL http://www.kspst.or.kr
    • 자료유형 학술저널
    • 수록면 527-539 ( 13쪽)
    • 언어 English
    • 출판년도 2018
    • 등재정보 KCI등재
    • 판매처
    유사주제 논문( 0)

' Nano delivery systems and cancer immunotherapy' 의 참고문헌

  • Why current peptide-based cancer vaccines fail: lessons from the three Es
    Claesson MH [2009]
  • Treatment of metastatic melanoma: an overview
    Bhatia S [2009]
  • Transforming growth factor-<TEX>${\beta}$</TEX> and the immune response: Implications for anticancer therapy
  • Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer
  • Therapeutic potential of toll-like receptor 9 activation
    Krieg AM [2006]
  • Therapeutic cancer vaccines: past, present, and future
    Guo C [2013]
  • The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy
    Smits ELJM. [2008]
  • The innate immune DNA sensor cGAS produces a noncanonical cyclic dinucleotide that activates human STING
    Diner EJ [2013]
  • The history of Tolllike receptors-redefining innate immunity
  • The basis of oncoimmunology
    Palucka AK [2016]
  • The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition
    Jiang X [2013]
  • Structural basis of the drug-binding specificity of human serum albumin
    Ghuman J [2005]
  • STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors
    Woo SR [2014]
  • Radiation-enhanced delivery of systemically administered amphiphilic-CpG oligodeoxynucleotide
    Appelbe OK [2017]
  • RNA vaccines in cancer treatment
    Bringmann A [2010]
  • Pyropheophorbide 2-deoxyglucosamide: a new photosensitizer targeting glucose transporters
    Zhang M [2003]
  • Prussian blue nanoparticlebased photothermal therapy combined with checkpoint inhibition for photothermal immunotherapy of neuroblastoma
  • Programmable co-delivery of the immune checkpoint inhibitor NLG919 and chemotherapeutic doxorubicin via a redox-responsive immunostimulatory polymeric prodrug carrier
    Sun J [2017]
  • Primary, adaptive, and acquired resistance to cancer immunotherapy
    Sharma P [2017]
  • Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy
    Chen Q [2016]
  • Photonics immunotherapy-a novel strategy for cancer treatment
    Zhou F [2016]
  • Photodynamic therapy of cancer: an update
    Agostinis P [2011]
  • PD-L1 expression in triple-negative breast cancer
  • PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-Associated head and neck cancer
    Badoual C [2013]
  • PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8+ T cells induced by melanoma vaccines
    Fourcade J [2014]
  • PD-1 and PD-L1 inhibitors as salvage therapy for urothelial carcinoma
    Sonpavde G [2017]
  • Nivolumab plus ipilimumab in advanced melanoma
    Wolchok JD [2013]
  • New developments in Toll-like receptor targeted therapeutics
    Connolly DJ [2012]
  • Nanoparticle vaccines
    Zhao L [2014]
  • Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression
    Lu J [2017]
  • Myeloid-derived suppressor cells as regulators of the immune system
  • Metal-organic framework (MOF)-based drug/cargo delivery and cancer therapy
    Wu MX [2017]
  • Mechanisms of resistance to immune checkpoint inhibitors
    Jenkins RW [2018]
  • Light-switchable systems for remotely controlled drug delivery
    Shim G [2017]
  • Inflammationtriggered cancer immunotherapy by programmed delivery of CpG and anti-PD1 antibody
    Wang C [2016]
  • Improved survival with ipili-mumab in patients with metastatic melanoma
    Hodi FS [2010]
  • Immunostimulatory oligonucleotidesloaded cationic graphene oxide with photothermally enhanced immunogenicity for photothermal/immune cancer therapy
    Tao Y [2014]
  • Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy
    Pfirschke C [2016]
  • Immunogenic cell death in cancer therapy
    Kroemer G [2013]
  • Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine
  • IDO1 in cancer: a Gemini of immune checkpoints
    Zhai L [2018]
  • IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance
    Munn DH [2016]
  • Hollow <TEX>$MnO_{2}$</TEX> as a tumor-microenvironment-responsive biodegradable nano-platform for combination therapy favoring antitumor immune responses
    Yang G [2017]
  • Graphene-based nanosheets for delivery of chemotherapeutics and biological drugs
    Shim G [2016]
  • Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy
    Liu Y [2017]
  • Designer vaccine nanodiscs for personalized cancer immunotherapy
    Kuai R [2016]
  • Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy
    He C [2016]
  • Combining vasculature disrupting agent and Toll-like receptor 7/8 agonist for cancer therapy
    Seth A [2017]
  • Combining immune checkpoint inhibitors and kinaseinhibiting supramolecular therapeutics for enhanced anticancer efficacy
    Kulkarni A [2016]
  • Combined chemotherapy and photodynamic therapy using a nanohybrid based on layered double hydroxides to conquer cisplatin resistance
    Wang Z [2015]
  • Combination immunotherapy of MUC1 mRNA nano-vaccine and CTLA-4 blockade effectively inhibits growth of triple negative breast cancer
    Liu L [2018]
  • Combination delivery of TGF-<TEX>${\beta}$</TEX> inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy
    Park J [2012]
  • Chlorin-based nanoscale metal-organic framework systemically rejects colorectal cancers via synergistic photodynamic therapy and checkpoint blockade immunotherapy
    Lu K [2016]
  • Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
    Casares N [2005]
  • Cancer despite immunosurveillance: immunoselection and immunosubversion
    Zitvogel L [2006]
  • CGAS produces a 2'-5'-linked cyclic dinucleotide second messenger that activates STING
    Ablasser A [2013]
  • Biodegradable hollow mesoporous silica nanoparticles for regulating tumor microenvironment and enhancing antitumor efficiency
    Kong M [2017]
  • Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy
    Wilson DR [2018]
  • Antagonists of PD-1 and PD-L1 in cancer treatment
    Lipson EJ [2015]
  • An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy
    Chen Y [2016]
  • An endogenous vaccine based on fluorophores and multivalent immunoadjuvants regulates tumor micro-environment for synergistic photothermal and immunotherapy
    Li L [2018]
  • All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients
    Mirza N [2006]
  • Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy
    Zhu G [2017]
  • Acid-activatable versatile micelleplexes for PD-L1 blockade-enhanced cancer photodynamic immunotherapy
    Wang D [2016]
  • A review of indocyanine green fluorescent imaging in surgery
    Alander JT [2012]
  • A cisplatin-loaded immuno-chemotherapeutic nanohybrid bearing immune checkpoint inhibitors for enhanced cervical cancer therapy
    Wang N [2018]
  • A STING-activating nanovaccine for cancer immunotherapy
    Luo M [2017]